A knockdown-and-replace gene therapy from Penn researchers shows promise in rare eye disease
It’s been a year of great strides in gene therapy, with Spark’s Luxturna earning the first US regulatory approval in the field for inherited blindness …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
